|
| | Bendamustine Basic information |
| Product Name: | Bendamustine | | Synonyms: | Bendamustine;4-[5-[Bis(2-chloroethyl)amino]-1-methyl-benzimidazol-2-yl]butyric acid hydrochloride;Bendamustine USP/EP/BP;Phenol,5-iodo-7-methyl- | | CAS: | 97832-05-8 | | MF: | C16H21Cl2N3O2.HCl | | MW: | 394.72 | | EINECS: | | | Product Categories: | API | | Mol File: | 97832-05-8.mol |  |
| | Bendamustine Chemical Properties |
| | Bendamustine Usage And Synthesis |
| Uses | Bendamustine is an intermediate in the synthesis of Bendamustine 3-Hydroxyprop-2-yl Ester (B132550), which is an impurity of anticancer drug Bendamustine Hydrochloride (B132500). | | Enzyme inhibitor | This nitrogen mustard and anticancer drug (FWfree-acid = 358.26 g/mol; CAS
16506-27-7), also known by its code name SDX-105, its trade names
Treanda?, Treakisym?, Ribomustin?, and Levact?, as well as by its
systematic name 4-[5-[bis (2-chloroethyl) amino]-1-methylbenzimidazol-2-
yl]butanoic acid, is a relatively nonspecific DNA alkylating agent that
causes intra- and inter-strand cross-links. Bendamustine is used in the
treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, non-
Hodgkin’s lymphoma, multiple myeloma and lung cancer.
Pharmacokinetics: After intravenous infusion, >95% of the drug becomes
protein-bound, mainly to albumin; however, only free bendamustine is
active. Bendamustine is metabolized by liver cytochrome p450, and
elimination (renal) is biphasic, with an initial half-life of 6–10 minutes and a
terminal half-life of approximately 30 minutes. |
| | Bendamustine Preparation Products And Raw materials |
|
